ArticleDermatology and therapy2026
Achieving Canadian Treat-to-Target Criteria in Moderate-to-Severe Atopic Dermatitis: A Retrospective Analysis of Outcomes from Real-World Canadian Practice.
Article in Dermatology and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionTreat-to-target (T2T) is a clinical paradigm intended to improve disease outcomes using measurement-based goals. Various groups of dermatologists have made T2T recommendations for managing moderate-to-severe atopic dermatitis (AD). These are based primarily on expert opinion, and their relevance for real-world outcomes has received limited attention. The objective of the present analysis was to assess the relevance of Canadian T2T criteria for moderate-to-severe AD in real-world practice by describing the agreement between achieving criteria and treatment decisions.
methodsCanadian dermatologists conducted retrospective chart reviews of adult patients with moderate-to-severe AD treated with an advanced systemic therapy (AST) in clinical practice. T2T criteria were applied to patient outcomes and treatment decisions were reported.
resultsCharts were reviewed for 297 patients who were assessed a combined 503 times over up to 1 year of treatment. Treatment modifications were made in less than 10% (38/425, 9%) of cases where patients met target and more than half (41/78, 53%) where they missed target. For patients missing target, switching AST was the most common modification.
conclusionsTreatment decisions were generally aligned with the retrospectively applied Canadian T2T criteria. While these results require further validation, they suggest that the T2T criteria represent valid thresholds for clinical decision-making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.